1,155 research outputs found
sj-pdf-1-ang-10.1177_00033197211065795 – Supplemental Material for The Association of Physical Activity with Arterial Stiffness and Inflammation: Insight from the “Corinthia” Study
No full textSupplemental Material, sj-pdf-1-ang-10.1177_00033197211065795 for The Association of Physical Activity with Arterial Stiffness and Inflammation: Insight from the “Corinthia” Study by Panagiotis Theofilis, Evangelos Oikonomou, George Lazaros, Georgia Vogiatzi, Vasiliki C Mystakidi, Athina Goliopoulou, Maria Anastasiou, Evangelia Christoforatou and Dimitris Tousoulis in Angiology</p
Supplemental Material—Expression of Tissue microRNAs in Ascending Aortic Aneurysms and Dissections
No full textSupplemental Material for Expression of Tissue microRNAs in Ascending Aortic Aneurysms and Dissections by Athina Goliopoulou, MD, Evangelos Oikonomou, MD, Alexis Antonopoulos, MD, Nikolaos Koumallos, MD, Maria Gazouli, PhD, Panagiotis Theofilis, MD, Vasiliki-Chara Mystakidi, MD, Panteleimon Pantelidis, MD, Michael-Andrew Vavuranakis, MD, Gerasimos Siasos, MD, and Dimitris Tousoulis, MD in Angiology</p
Inflammatory disorders and atherosclerosis: new therapeutic approaches
No full textRecent evidence suggests that patients with chronic inflammatory disorders are at increased cardiovascular risk. A number of different mechanisms have been postulated to contribute to atherosclerotic disease progression in these patients including traditional cardiovascular risk factors, cytokine upregulation, immume mediated pathways and increased oxidative stress. Novel treatments target inflammatory pathways and have beneficial effect on rheumatic disease activity however; their impact on cardiovascular risk reduction remains unclear. Further longitudinal studies are required to assess the value of different therapeutic approaches on cardiovascular outcome of these patients
The role of colchicine in pericardial syndromes
No full textBackground: Colchicine is an old drug originally employed for the treatment of inflammatory disorders such as acute gout and familiar Mediterranean fever. Methods: In the past few decades, colchicine has been at the forefront of the pharmacotherapy of several cardiac diseases, including acute and recurrent pericarditis, coronary artery disease, prevention of atrial fibrillation and heart failure. In this review, we have summarized the current evidence based medicine and guidelines recommendations in the specific context of pericardial syndromes. Results: Colchicine has been firstly engaged in the treatment of recurrent pericarditis of viral, idiopathic and autoimmune origin. Shortly thereafter colchicine use has been expanded to the primary prevention of recurrences in patients with a first episode of pericarditis depicting similarly good results. The acquisition of high quality scientific data in the course of time from prospective randomized placebo-controlled trials and metanalyses have established colchicine as first line treatment option in acute and recurrent pericarditis, on top of the conventional treatment. The only concerns related to the use of colchicine are the side effects (mainly gastrointestinal intolerance) which although generally not serious, may account for treatment withdrawal in some cases. Conclusion: Colchicine has been established as a first line medication in the treatment of acute (first episode) and recurrent pericarditis on top of the conventional treatment as well as for the prevention of postpericardiotomy syndrome. It depicts a good safety profile with gastrointestinal intolerance being the most common side effect
New modalities assessing left and right ventricular function: How they apply to myocardial infarction
No full text
- …
